[ET Net News Agency, 12 January 2024] J.P. Morgan raised its target price for WuXi Bio
(02269) to HKD34 from HKD33 and maintained its "neutral" rating.
The research house said it models FY23E/FY24E revenue growth of 10% and 14%,
respectively, and FY23E/FY24E adjusted net profit growth of -6% and 13%, respectively.
(RC)